Study sheds new light on aggressive cancer in children

A cancer cell
03 Feb 2015 14:20:06.037
PA 21/15

A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never before seen flood of mutations in their disease in just six months.

The syndrome, called ‘biallelic mismatch repair deficiency’ (bMMRD) causes multiple brain tumours, lymphomas and gastrointestinal cancers by the age of 10. As a result these children rarely survive into adulthood. 

While most cancers grow progressively, developing genetic mutations over many years, researchers at The Hospital for Sick Kids in Toronto, Canada, the Wellcome Trust Sanger Institute and the Children’s Brain Tumour Research Centre in Nottingham, were shocked to find that children with this syndrome develop more mutations than any human cancers by far — as many as 20,000 mutations in as little as six months.
Click here for full story
The new paper, published online in Nature Genetics, suggests a previously undiscovered mechanism for cancer progression which could lead to more targeted treatment for these patients and indeed for more common cancers.

‘Great flood’ 

Children with biallelic mismatch repair deficiency, or bMMRD, have mutations in the genes responsible for mismatch repair and therefore cannot fix mistakes in DNA while the cell is dividing (or replicating). This study identifies a secondary mutation which occurs only in tumour cells in an enzyme called polymerase, which is a second safeguard that helps to effectively repair mutations while the DNA replicates. The combination of these two mutations leaves patients with no ability to repair mistakes that may occur while DNA is replicating, and causes a rapid wave of cancer that the investigators have dubbed the “great flood.”

Professor Richard Grundy from the University’s Children’s Brain Tumour Research Centre said: “This study provides a major step forwards in understanding why certain children are more susceptible to developing multiple cancers and can screen for this eventuality. In turn, this study allows us to begin to understand the steps that lead to cancer developing. Ultimately, we hope this leads to treatments to avoid the presently inevitable consequences of this predisposition syndrome”

Implications for diagnosis and treatment

Dr Uri Tabori, co-principal investigator of the study from Genetics & Genome Biology at SickKids, Toronto said: “In other cancer predisposition syndromes like BRCA1 and Li Fraumeni syndrome, we know that there is a genetic mutation that predisposes the individual to cancer, but we do not know the secondary mutation, or genetic driver that actually causes the cancer to occur. Our findings indicate the genetic driver that causes this ‘great flood’ of cancer mutations in patients with bMMRD. The secondary mutation in the enzyme polymerase causes a unique signature of mutations that is present in 100 per cent of the cases. This has important implications for both diagnosis and targeted treatment of this devastating disease.”

International consortium for cancer genetics

The Children’s Brain Tumour Research Centre in Nottingham is part of an international consortium run by SickKids, Toronto, that offers free genetic testing, genetic counseling and surveillance of cancers in children and family members with bMMRD. Using genetic and clinical information and tumour samples gathered from each patient, the research team was able to take a deeper look at this cancer predisposition syndrome and for the first time they are able to tell the story of how this cancer develops.

“We were able to describe how many mutations develop, how fast they occur, how many mutations the tumour can sustain, and the type of mutation that occurs, which we found is unique to bMMRD cancers,” says Dr Adam Shlien, lead author of the study and Associate Director of Translational Genetics and Scientist in Genetics & Genome Biology at SickKids. 

“Additionally, by studying a rare cancer syndrome we were able to have an unobstructed view on how cancer develops and learn not only about how we can help these patients, but also about cancer progression in general.”

Because the high number of mutations is so specific to bMMRD syndrome, researchers are now able to detect children who are carriers just by sequencing the tumour. 

“If the child has a very high number of mutations then we know immediately that they have this cancer predisposition syndrome,” said Dr Shlien. 

Towards tumour cell death

The team may have also found a clue that may help to develop a novel treatment that promotes tumour cell death. The observation that tumour cells reach a threshold of 20,000 mutations and cannot overcome it suggests that the tumour cannot withstand any more, and more mutations may cause cell death. Future research may explore how certain pharmacological agents may push these cancer cells over the mutational edge and cause the tumour cells to die. 
It’s hoped findings from this study will also lead to more effective treatments for more common cancers such as colon, gynaecological cancers and recurrent malignant gliomas (cancer in the brain or spine) since they share the same mutations in the mismatch repair genes as bMMRD patients).

The study was supported by BRAINchild Canada, the Canadian Institutes of Health Research (CIHR), Wellcome Trust Sanger Institute and SickKids Foundation.

— Ends —

Our academics can now be interviewed for broadcast via our Media Hub, which offers a Globelynx fixed camera and ISDN line facilities at University Park campus. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email or see the Globelynx website for how to register for this service.

For up to the minute media alerts, follow us on Twitter

Notes to editors: The University of Nottingham has 43,000 students and is ‘the nearest Britain has to a truly global university, with campuses in China and Malaysia modelled on a headquarters that is among the most attractive in Britain’ (Times Good University Guide 2014). It is also one of the most popular universities in the UK among graduate employers, in the top 10 for student experience according to the Times Higher Education and winner of ‘Research Project of the Year’ at the THE Awards 2014. It is ranked in the world’s top one per cent of universities by the QS World University Rankings, and 8th in the UK by research power according to REF 2014.

The University of Nottingham in Malaysia (UNMC) is holding events throughout 2015 to celebrate 15 years as a pioneer of transnational education. Based in Semenyih, UMNC was established as the UK's first overseas campus in Malaysia and one of the first world-wide.

Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…

Story credits

More information is available from Professor Richard Grundy, in the School of Medicine, University of Nottingham on +44 (0)115 823 0620, 

Additional resources

No additional resources for this article

Related articles

A new bright light source to speed up cancer diagnosis

Published Date
Thursday 26th February 2015

Going the extra mile for Children's Brain Tumour Research

Published Date
Friday 8th August 2014

Preserving fertility among young cancer patients

Published Date
Thursday 19th February 2015

Riding in support of brain tumour research

Published Date
Thursday 1st May 2014

New cell model to speed up development of brain tumour drugs

Published Date
Friday 5th September 2014

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798